Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

The size of India’s insulin market was an estimated Rs 4,404 crore in April this year, with Indian players making steady ...

President Trump’s executive order aims to bring down drug prices while optimizing IP protections, and Congress should pass ...

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

Swiss President Karin Keller-Sutter will visit pharma powerhouse Ireland tomorrow for high-level talks ahead of President ...

Pharmaceutical companies are making billions on treatments that can sometimes overpromise and underdeliver for terminal cases ...

The supply of GLP-1 drugs has been increasing, but they’re still expensive for most patients. Here are answers to some ...

The Trump administration's escalating calls for drug companies to lower prices underscore just how stuck the industry is in ...

President Donald Trump’s proposal to peg US drug prices to those paid abroad includes granting the FDA legal authority to ...

However, President Trump has publicly stated that pharmaceutical import tariffs are on the way. Earlier this year, he proposed levying 25% tariffs on imported drugs. Lilly CEO Dave Ricks acknowledged ...

Independent pharmacists worry that tariffs could drive companies out of business while raising prices and creating drug ...